Advanced search
1 file | 11.79 MB Add to list

A VersaTile approach to reprogram the specificity of the R2-type tailocin towards different serotypes of Escherichia coli and Klebsiella pneumoniae

Author
Organization
Project
Abstract
Background: Phage tail-like bacteriocins, or tailocins, provide a competitive advantage to producer cells by killing closely related bacteria. Morphologically similar to headless phages, their narrow target specificity is determined by receptor-binding proteins (RBPs). While RBP engineering has been used to alter the target range of a selected R2 tailocin from Pseudomonas aeruginosa, the process is labor-intensive, limiting broader application. Methods: We introduce a VersaTile-driven R2 tailocin engineering and screening platform to scale up RBP grafting. Results: This platform achieved three key milestones: (I) engineering R2 tailocins specific to Escherichia coli serogroups O26, O103, O104, O111, O145, O146, and O157; (II) reprogramming R2 tailocins to target, for the first time, the capsule and a new species, specifically the capsular serotype K1 of E. coli and K11 and K63 of Klebsiella pneumoniae; (III) creating the first bivalent tailocin with a branched RBP and cross-species activity, effective against both E. coli K1 and K. pneumoniae K11. Over 90% of engineered tailocins were effective, with clear pathways for further optimization identified. Conclusions: This work lays the groundwork for a scalable platform for the development of engineered tailocins, marking an important step towards making R2 tailocins a practical therapeutic tool for targeted bacterial infections.
Keywords
tailocin, phage tail-like bacteriocin, R2 pyocin, receptor-binding protein, tailspike, VersaTile, phage-host interactions, Klebsiella pneumoniae, Escherichia coli, R-TYPE PYOCINS, PSEUDOMONAS-AERUGINOSA, BACTERIOCIN, PURIFICATION, PROTEIN, BACTERIOPHAGES, INFECTION, PHAGES, MODEL, TALE

Downloads

  • antibiotics-14-00104.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 11.79 MB

Citation

Please use this url to cite or link to this publication:

MLA
Dams, Dorien, et al. “A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin towards Different Serotypes of Escherichia Coli and Klebsiella Pneumoniae.” ANTIBIOTICS-BASEL, vol. 14, no. 1, 2025, doi:10.3390/antibiotics14010104.
APA
Dams, D., Pas, C., Łątka, A., Drulis-Kawa, Z., Fieseler, L., & Briers, Y. (2025). A VersaTile approach to reprogram the specificity of the R2-type tailocin towards different serotypes of Escherichia coli and Klebsiella pneumoniae. ANTIBIOTICS-BASEL, 14(1). https://doi.org/10.3390/antibiotics14010104
Chicago author-date
Dams, Dorien, Célia Pas, Agnieszka Łątka, Zuzanna Drulis-Kawa, Lars Fieseler, and Yves Briers. 2025. “A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin towards Different Serotypes of Escherichia Coli and Klebsiella Pneumoniae.” ANTIBIOTICS-BASEL 14 (1). https://doi.org/10.3390/antibiotics14010104.
Chicago author-date (all authors)
Dams, Dorien, Célia Pas, Agnieszka Łątka, Zuzanna Drulis-Kawa, Lars Fieseler, and Yves Briers. 2025. “A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin towards Different Serotypes of Escherichia Coli and Klebsiella Pneumoniae.” ANTIBIOTICS-BASEL 14 (1). doi:10.3390/antibiotics14010104.
Vancouver
1.
Dams D, Pas C, Łątka A, Drulis-Kawa Z, Fieseler L, Briers Y. A VersaTile approach to reprogram the specificity of the R2-type tailocin towards different serotypes of Escherichia coli and Klebsiella pneumoniae. ANTIBIOTICS-BASEL. 2025;14(1).
IEEE
[1]
D. Dams, C. Pas, A. Łątka, Z. Drulis-Kawa, L. Fieseler, and Y. Briers, “A VersaTile approach to reprogram the specificity of the R2-type tailocin towards different serotypes of Escherichia coli and Klebsiella pneumoniae,” ANTIBIOTICS-BASEL, vol. 14, no. 1, 2025.
@article{01JJJ66WCCGCBBPVAZ63XTGAVV,
  abstract     = {{Background: Phage tail-like bacteriocins, or tailocins, provide a competitive advantage to producer cells by killing closely related bacteria. Morphologically similar to headless phages, their narrow target specificity is determined by receptor-binding proteins (RBPs). While RBP engineering has been used to alter the target range of a selected R2 tailocin from Pseudomonas aeruginosa, the process is labor-intensive, limiting broader application. Methods: We introduce a VersaTile-driven R2 tailocin engineering and screening platform to scale up RBP grafting. Results: This platform achieved three key milestones: (I) engineering R2 tailocins specific to Escherichia coli serogroups O26, O103, O104, O111, O145, O146, and O157; (II) reprogramming R2 tailocins to target, for the first time, the capsule and a new species, specifically the capsular serotype K1 of E. coli and K11 and K63 of Klebsiella pneumoniae; (III) creating the first bivalent tailocin with a branched RBP and cross-species activity, effective against both E. coli K1 and K. pneumoniae K11. Over 90% of engineered tailocins were effective, with clear pathways for further optimization identified. Conclusions: This work lays the groundwork for a scalable platform for the development of engineered tailocins, marking an important step towards making R2 tailocins a practical therapeutic tool for targeted bacterial infections.}},
  articleno    = {{104}},
  author       = {{Dams, Dorien and Pas, Célia and Łątka, Agnieszka and Drulis-Kawa, Zuzanna and Fieseler, Lars and Briers, Yves}},
  issn         = {{2079-6382}},
  journal      = {{ANTIBIOTICS-BASEL}},
  keywords     = {{tailocin,phage tail-like bacteriocin,R2 pyocin,receptor-binding protein,tailspike,VersaTile,phage-host interactions,Klebsiella pneumoniae,Escherichia coli,R-TYPE PYOCINS,PSEUDOMONAS-AERUGINOSA,BACTERIOCIN,PURIFICATION,PROTEIN,BACTERIOPHAGES,INFECTION,PHAGES,MODEL,TALE}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{28}},
  title        = {{A VersaTile approach to reprogram the specificity of the R2-type tailocin towards different serotypes of Escherichia coli and Klebsiella pneumoniae}},
  url          = {{http://doi.org/10.3390/antibiotics14010104}},
  volume       = {{14}},
  year         = {{2025}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: